138071-82-6

Basic information

• Product Name: Gadobutrol
• Synonyms: Gadobutrol;GadoliniuM,[10-[2,3-dihydroxy-1-(hydroxyMethyl)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-kN1,kN4,kN7,kN10,kO1,kO4,kO7]-;gallium 10-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylate;CL124;gadolinium(III) 2,2',2''-(10-((2R,3S)-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
• CAS NO: 138071-82-6
• Molecular Formula: C18H31N4O9.Gd
• Molecular Weight: 604.712
• EINECS: 1308068-626-2
• Product Categories: API
• Mol File: 138071-82-6.mol

Chemical Properties

• Boiling Point: 738.5°Cat760mmHg
• Flash Point: 400.4°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 3.59E-25mmHg at 25°C
• Storage Temp.: Refrigerator
• Solubility: Water (Slightly)
• CAS DataBase Reference: Gadobutrol(CAS DataBase Reference)
• NIST Chemistry Reference: Gadobutrol(138071-82-6)
• EPA Substance Registry System: Gadobutrol(138071-82-6)

Safety Data

• Hazardous Substances Data: 138071-82-6(Hazardous Substances Data)

Usage

Uses

Gadobutrol is a gadolinium-based MRI contrast agent (GBCA).

Uses

Gadobutrol injection is a magnetic resonance imaging (MRI) contrast agent that is used to help create a clear picture of the body during an MRI scan. MRI scans are a special kind of procedure that lets a doctor look at the inside of the body, such as the brain.

Mechanism of action

In the central nervous system, Gadobutrol works by highlighting any areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity. In breast tissue, Gadobutrol exposes the presence and extent of malignant breast disease.

Waste Disposal

Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

InChI:InChI=1/C18H34N4O9.Ga/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3/t14-,15-;/m1./s1

Upstream product

• 13807-15-3 4-amino-2-anilino-thiazole-5-carboxamide 
• 1380698-48-5 2,4-bis(MethoxyMethoxy)-1-Methylbenzene 
• 138069-52-0 ukrain 
• 138068-93-6 pescaproside E 
• 138068-81-2 Opusfil 
• 138068-37-8 Lepirudin 
• 1380680-53-4 2-Ethynylpiperidine hydrochloride 
• 1380680-50-1 Piperidine, 4-(3,3-difluoro-1-azetidinyl)-, hydrochloride 
• 1380679-98-0 tert-butyl (2-amino-8-oxabicyclo[3.2.1]octan-6-yl)carbamate 
• 1380679-97-9 5-tert-Butyl 4-ethyl 3-methyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-4,5(4H)-dicarboxylate 
• 13806-78-5 m-Chlorobenzenethiocarboxylic acid O-ethyl ester 
• 138067-74-0 Acid Blue 350 
• 138067-71-7 BEC 
• 138067-56-8 calcium orange 

Downstream Products

• 1380723-44-3 Atezolizumab 
• 138072-88-5 HYDROTRIS(3-P-TOLYLPYRAZOL-1-YL)BORATE THALLIUM SALT 
• 138074-21-2 1,3-Difluor-5-[trans-4-(trans-4-propylcyclohexyl)-cyclohexyl]-benzol 
• 138074-23-4 1,3-Difluor-5-[trans-4-(trans-4-pentylcyclohexyl)-cyclohexyl]-benzol 
• 138-07-8 [1-(aminocarbonyl)hydrazino]acetic acid 
• 13807-84-6 (2-PHENOXYPHENYL)METHANOL 
• 138078-58-7 5-HYDROXYMETHYL-3-METHYLPYRROLIDIN-2-ONE 
• 13807-91-5 1-BENZYLOXY-2-PROPANOL 
• 138079-58-0 (R)-2,3-Dimethyl-4-(triphenylphosphoranylidene)-2-butanol 
• 13807-95-9 3-(4-Methoxybenzyloxy)-1,2-propanediol 
• 138079-59-1 (R)-(3-hydroxy-2,3-diMethylbutyl)triphenylphosphoniuM iodide 
• 138079-62-6 acetylanonamine 
• 138079-73-9 1-fluoroglucopyranosyl fluoride 
• 138079-74-0 N-BENZOYL-D-ALANYLTHIOGLYCOLIC ACID 

Related news

Gadobutrol (cas 138071-82-6) enhances T1-weighted MRI of nerve cells08/16/2019

Three-dimensional T1-weighted MRI of mouse brain in vivo (9.4 T, 80 μm isotropic resolution) identified assemblies of nerve cell bodies in the habenula, hippocampal formation, locus coeruleus, dorsal motor nucleus of vagus, and nucleus ambiguus as high signal intensities, while suppressing the ...detailed